Primary Central Nervous System Lymphoma (PCNSL) — Cost, Top Hospitals & Success Rates | MyMedicPlus

Primary Central Nervous System Lymphoma (PCNSL) is a rare and aggressive extranodal non-Hodgkin lymphoma (NHL) confined at diagnosis to the brain, spinal cord, eyes (vitreoretinal compartment), or leptomeninges, without systemic lymphoma. It is a distinct and highly treatment-sensitive entity that is universally fatal if untreated but potentially curable with modern high-dose methotrexate (HD-MTX)-based chemoimmunotherapy.

Histologically, PCNSL is diffuse large B-cell lymphoma (DLBCL) in over 90% of immunocompetent patients, with an activated B-cell (ABC) phenotype predominating, arising from post-germinal centre B-cells that have trafficked into the CNS immune sanctuary. The remaining ~10% include follicular lymphoma, marginal zone lymphoma, and T-cell lymphoma variants.

Epidemiology: PCNSL has an incidence of approximately 0.47 per 100,000 person-years in the UK, accounting for 2–5% of primary brain tumours and approximately 4% of all NHL. The median age at diagnosis in immunocompetent patients is approximately 65 years, with a slight male preponderance. A second peak occurs in younger immunocompromised patients, most notably those with untreated HIV infection (AIDS-related PCNSL — almost exclusively Epstein-Barr virus (EBV)-driven DLBCL). The incidence of PCNSL has been rising steadily over the past three decades, particularly in the elderly population aged over 70.

Anatomical Distribution: PCNSL most commonly involves the cerebral hemispheres (38%), thalami/basal ganglia (16%), corpus callosum, and periventricular white matter. Cerebellar and brainstem involvement occurs in approximately 12% of cases. Multifocal disease at presentation is seen in 35–50% of patients. Vitreoretinal lymphoma (VRL) coexists with intracranial PCNSL in approximately 15–20% of cases and can precede or follow the cerebral diagnosis by months to years.

The prognosis of PCNSL has improved substantially with modern HD-MTX-based regimens and autologous stem cell transplant (ASCT) consolidation, but PCNSL in elderly and frail patients — who cannot tolerate intensive treatment — remains a major clinical challenge with poor outcomes.

The PCNSL treatment framework addresses several distinct clinical presentations and related conditions:

1. Immunocompetent PCNSL (the majority)

Occurring in adults without immunosuppression, this subtype has the best prognosis with modern treatment. DLBCL is the predominant histology. Molecular profiling demonstrates recurrent mutations in MYD88 L265P (approximately 70%), CD79B (approximately 60%), and BCL6 rearrangements — a distinctive mutational signature differentiating PCNSL from systemic DLBCL and forming the basis for targeted therapies including BTK inhibitors.

2. AIDS-Related PCNSL

Occurring in patients with advanced HIV and CD4 count typically below 50 cells/mcL, this subtype is almost universally EBV-positive on in situ hybridisation. In the era before effective antiretroviral therapy (ART), prognosis was extremely poor (median survival weeks). With modern ART achieving virological suppression, AIDS-related PCNSL can be treated analogously to immunocompetent PCNSL, with substantially improved outcomes.

3. Post-Transplant PCNSL

Occurring in solid organ or haematopoietic stem cell transplant recipients on calcineurin inhibitor-based immunosuppression, post-transplant PCNSL is typically EBV-driven. Reduction of immunosuppression is the first intervention; rituximab monotherapy and EBV-directed T-cell therapies are emerging approaches.

4. Vitreoretinal Lymphoma (VRL)

VRL presenting without simultaneous CNS disease is classified as primary vitreoretinal lymphoma (PVRL). Over 65–90% of PVRL cases will eventually develop PCNSL. Treatment includes intravitreal methotrexate and/or rituximab, combined with systemic HD-MTX-based chemoimmunotherapy if concurrent or subsequent CNS involvement is confirmed. Specialist ophthalmology involvement is mandatory for vitreous biopsy (vitrectomy) and slit-lamp examination.

5. Leptomeningeal Lymphoma

Lymphomatous leptomeningeal involvement may accompany cerebral PCNSL. CSF cytology, flow cytometry (sensitivity 70–80%), and next-generation sequencing are used to detect leptomeningeal lymphoma cells. Intrathecal chemotherapy (methotrexate, cytarabine) via Ommaya reservoir may supplement systemic HD-MTX in CSF-positive disease.

Treatment eligibility for intensive PCNSL regimens is determined by a combination of performance status, organ function, age, comorbidities, and the intended treatment strategy:

• ECOG performance status: Patients with ECOG PS 0–2 are generally eligible for intensive HD-MTX-based induction and ASCT consolidation. Patients with PS 3–4 may be candidates for reduced-intensity HD-MTX monotherapy or corticosteroid-based palliative treatment.
• Renal function: HD-MTX is renally cleared. A creatinine clearance (Cockcroft-Gault) ≥50 mL/min is the minimum threshold for standard-dose HD-MTX administration. Dose reduction or alternative schedules are required for impaired renal function. Leucovorin rescue timing and frequency must be adjusted for renal clearance. Post-cycle monitoring of serum methotrexate levels is mandatory until clearance is achieved (<0.1 micromol/L).
• Hepatic function: Moderate-to-severe hepatic impairment (bilirubin >3× ULN, transaminases >5× ULN) requires dose reduction or temporary withholding of chemotherapy components.
• Age considerations: PCNSL disproportionately affects elderly patients. The IELSG-32 (MATRix) trial demonstrated that the MATRix regimen is feasible in patients up to age 70, with acceptable toxicity. For patients aged 70+, comprehensive geriatric assessment (CGA) should guide fitness stratification. The International Extranodal Lymphoma Study Group (IELSG) and British Society of Haematology (BSH) recommend reduced-intensity HD-MTX ± rituximab as first-line treatment for patients not fit for MATRix or ASCT.
• Diagnostic confirmation before treatment: Corticosteroids must be withheld before stereotactic biopsy unless life-threatening cerebral oedema mandates their use. Corticosteroids cause rapid lymphoma lysis and can render tumour tissue non-diagnostic in 30–50% of cases, delaying definitive diagnosis. If steroids have been administered, biopsy should be deferred for at least 72 hours if clinically safe.
• HIV status: All patients with newly diagnosed PCNSL should be tested for HIV, as AIDS-related PCNSL requires concurrent ART initiation.

PCNSL treatment is complex and requires a multidisciplinary team including neuro-oncology, haematology, radiation oncology, ophthalmology, and neurosurgery. All newly diagnosed patients should be discussed at a specialist CNS lymphoma MDT and, where possible, enrolled in clinical trials.

1. Induction Chemoimmunotherapy

The gold-standard induction regimen is MATRix (HD-MTX 3.5 g/m² + cytarabine 2 g/m² bd + rituximab 375 mg/m² + thiotepa 30 mg/m²), derived from the IELSG-32 randomised trial (N=219). The MATRix arm achieved a complete or unconfirmed complete response (CR/CRu) rate of 49% compared to 23% for HD-MTX/cytarabine alone (p=0.006). The 2-year OS was 69% in the MATRix arm.

Prior landmark trials:

• IELSG-20 (Ferreri et al., Lancet 2009): First RCT demonstrating superiority of HD-MTX + cytarabine over HD-MTX alone (CR rate 46% vs 18%; 3-year OS 46% vs 32%).
• IELSG-32 (MATRix) (Ferreri et al., Lancet Haematol 2016): Established 4-drug MATRix as the new standard. Addition of rituximab and thiotepa to HD-MTX/cytarabine significantly improved response rates and OS in immunocompetent patients up to age 70.

2. Consolidation Strategies

• Autologous Stem Cell Transplant (ASCT): The MATRix-RICE trial demonstrated that thiotepa-BCNU conditioning ASCT is the preferred consolidation strategy for transplant-eligible patients achieving CR after MATRix induction. 2-year PFS with ASCT was significantly superior to WBRT consolidation.
• Whole-Brain Radiotherapy (WBRT): WBRT (23.4–36 Gy in 13–20 fractions) achieves high CNS response rates but carries a significant risk of delayed neurotoxicity — cognitive decline, white matter leukoencephalopathy, and dementia — particularly in patients aged over 60 who have received prior HD-MTX. WBRT is now reserved for elderly patients unfit for ASCT, or as salvage therapy. The PRECIS trial demonstrated that consolidation ASCT produced equivalent or superior outcomes to WBRT with lower neurotoxic risk.
• Reduced-dose WBRT (23.4 Gy) is used in some centres for elderly patients with good response to induction, balancing tumour control with neurotoxicity reduction.

3. Relapsed/Refractory PCNSL

• BTK inhibitors: Ibrutinib achieves response rates of 50–75% in relapsed/refractory PCNSL, exploiting the near-universal MYD88 L265P / CD79B mutation signature. Zanubrutinib and acalabrutinib have CNS penetration and are under investigation. Combination ibrutinib + HD-MTX or ibrutinib + temozolomide/rituximab/dexamethasone (TEDdi-R) regimens are being evaluated in clinical trials.
• HD-MTX re-challenge: Patients who responded to initial HD-MTX and relapsed after >12 months may respond to HD-MTX re-challenge in approximately 85% of cases (Plotkin et al.).
• CAR-T cell therapy: CD19-directed CAR-T therapies (tisagenlecleucel, axicabtagene ciloleucel) are being evaluated in PCNSL clinical trials, with early-phase results demonstrating CNS penetration and responses in small series.

The evidence base for PCNSL treatment has grown substantially over the past two decades, with iterative clinical trial improvements translating into meaningfully improved patient outcomes:

• Complete response rates: MATRix induction achieves CR/CRu in 49% of patients after 4 cycles. Among patients completing MATRix + ASCT consolidation, approximately 70–75% achieve durable CR at 2 years.
• 5-year overall survival: With modern HD-MTX-based induction and ASCT consolidation in transplant-eligible patients, 5-year OS rates of 30–50% are achievable in population-based series; single-centre series from specialist institutions report 5-year OS exceeding 50% in carefully selected transplant-eligible patients.
• Neurocognitive preservation: ASCT consolidation, compared with WBRT, is associated with better long-term neurocognitive outcomes. Prospective neuropsychological testing in the MATRix-RICE trial demonstrated significantly lower rates of cognitive decline in the ASCT versus WBRT arms at 2-year follow-up.
• Response to ibrutinib (R/R): The phase I/II trial by Grommes et al. (Blood 2017) reported an overall response rate of 77% with ibrutinib monotherapy in relapsed/refractory PCNSL, with some complete and durable remissions. Real-world response rates are approximately 50–70%.
• Vitreoretinal lymphoma: Intravitreal methotrexate achieves vitreous clearance in the majority of patients. Combining systemic and intravitreal treatment appears to reduce the rate of subsequent CNS lymphoma in PVRL patients compared with ocular treatment alone.
• Prognostic scoring: The IELSG Prognostic Score (age >60, ECOG PS >1, elevated LDH, elevated CSF protein, deep brain involvement) stratifies patients into low (0–1 factors; 2-year OS 80%), intermediate (2–3 factors; 2-year OS 48%), and high (4–5 factors; 2-year OS 15%) risk groups, informing treatment intensity and clinical trial eligibility.

PCNSL treatment with HD-MTX-based regimens is intensive and associated with significant acute and long-term toxicities:

Acute Toxicities of HD-MTX

• Nephrotoxicity: HD-MTX can precipitate in renal tubules, causing acute kidney injury. Mandatory hyperhydration (≥3 L/m²/day), urine alkalinisation (pH >7.0), and leucovorin rescue (commencing 24 hours post-infusion) mitigate but do not eliminate renal risk. Serum methotrexate levels must be monitored until clearance is confirmed (<0.1 micromol/L).
• Myelosuppression: Leukopenia, neutropenia, and thrombocytopenia are common during cytarabine and thiotepa cycles. G-CSF support is required. Febrile neutropenia requires immediate hospitalisation and broad-spectrum antibiotics per local haematology protocols.
• Mucositis: Oral and gastrointestinal mucositis occurs in approximately 20–30% of patients receiving MATRix. Prophylactic and therapeutic oral care protocols are essential.
• Hepatotoxicity: Transient transaminase elevation is common; dose delays may be required for significant hepatic dysfunction.

Long-Term Neurotoxicity

Delayed leukoencephalopathy — manifesting as progressive cognitive decline, gait disturbance, and urinary incontinence — is the most devastating long-term complication of PCNSL treatment and is predominantly associated with WBRT, particularly when combined with HD-MTX. It occurs in approximately 20–50% of long-term survivors receiving combined modality therapy and is more common in patients aged over 60. The shift towards ASCT consolidation rather than WBRT has substantially reduced neurotoxic morbidity in transplant-eligible patients.

ASCT-Specific Toxicities

Thiotepa-BCNU conditioning is associated with secondary cytopenias, infection risk during the engraftment period (approximately 14–21 days), hepatic sinusoidal obstruction syndrome (SOS/VOD), and secondary myelodysplastic syndrome (MDS) or acute myeloid leukaemia (AML) in approximately 2–5% of long-term survivors.

Ibrutinib-Specific Toxicities

Atrial fibrillation (5–15%), haemorrhage (including intracranial haemorrhage — of particular concern in a CNS tumour context), hypertension, opportunistic infections (notably Pneumocystis jirovecii pneumonia — PJP prophylaxis mandatory), and aspergillosis are key adverse effects requiring monitoring and prophylaxis.

Structured long-term follow-up is essential for PCNSL survivors, given the significant risks of late disease relapse and treatment-related neurotoxicity:

Response Assessment

The IPCG (International PCNSL Collaborative Group) response criteria use contrast-enhanced brain MRI to assess response: complete radiological response (CRu/CR), partial response (PR), stable disease (SD), or progressive disease (PD). Response assessment MRI is performed after 2 cycles of induction and at end of induction. PCNSL response assessment in the eye requires slit-lamp ophthalmological examination and, where indicated, vitreoretinal cytology.

Surveillance MRI Schedule

• Year 1: MRI brain (with gadolinium) every 3 months.
• Year 2: MRI every 4 months.
• Years 3–5: MRI every 6 months.
• Beyond year 5: Annual MRI or as clinically indicated.

The rationale for intensive early surveillance is that approximately 50–60% of PCNSL relapses occur within the first 2 years. Early detection of relapse enables timely salvage therapy, which is most effective in patients with good PS and adequate organ function at relapse.

Neuropsychological Assessment

Formal neuropsychological assessment (Hopkins Verbal Learning Test, Trail Making Test, Digit Span, Controlled Oral Word Association Test) should be performed at baseline, after completion of induction, and at 6-month and annual intervals thereafter. Early identification of cognitive decline enables referral for neuropsychological rehabilitation and adjustment of medications that may contribute to cognitive impairment (high-dose corticosteroids, opioids, anticholinergics).

Ophthalmological Surveillance

Annual slit-lamp examination and fundoscopy for vitreoretinal lymphoma is recommended for all PCNSL patients, given the 15–20% rate of ocular involvement and the possibility of asynchronous presentation.

Late Effects Monitoring

Annual assessment for secondary malignancies (particularly in ASCT recipients), thyroid function (if prior cranial irradiation), and pituitary function (if pituitary axis has been irradiated) is recommended. Endocrinological review should be sought if growth hormone deficiency, hypothyroidism, or hypogonadism is suspected.

PCNSL treatment is resource-intensive, reflecting the high cost of specialised chemotherapy regimens, prolonged hospital admissions, and transplant procedures:

• HD-MTX cycles: Each HD-MTX cycle requires inpatient admission for hyperhydration, MTX infusion, leucovorin rescue, and serum MTX level monitoring — typically 3–5 days per cycle. Drug costs for HD-MTX itself are modest (generic methotrexate), but nursing, monitoring, and hospital bed costs accumulate across 4–6 cycles of MATRix induction.
• Rituximab: Biosimilar rituximab (e.g., Truxima, Rixathon) is available at significantly reduced cost compared with reference rituximab (MabThera). NHS England and devolved health systems have mandated rituximab biosimilar use for eligible indications, substantially reducing per-cycle costs.
• Thiotepa: Thiotepa (Tepadina) is a high-cost component of both MATRix induction and ASCT conditioning. The cost of thiotepa for a full MATRix induction course is approximately £8,000–£15,000 per patient (NHS indicative pricing).
• Autologous stem cell transplant: ASCT (including mobilisation, stem cell harvest, cryopreservation, conditioning chemotherapy, and transplant inpatient stay) costs approximately £40,000–£70,000 in UK NHS specialist centres.
• Ibrutinib (Imbruvica): Ibrutinib list price is approximately £5,500–£6,500 per month. NHS England Blueteq approvals and Managed Access Agreements are required. Ibrutinib for PCNSL is not currently NICE-approved for this indication and is accessed via NHS Individual Funding Requests (IFR) or clinical trials.
• WBRT: A course of WBRT (23.4–36 Gy in 13–20 fractions, 4–5 weeks) in an NHS radiotherapy centre costs approximately £8,000–£15,000 and is less resource-intensive than ASCT, but carries the neurotoxic costs outlined above — including long-term care needs for treatment-related dementia.
• Medical tourism: Specialist PCNSL treatment is available at leading oncology centres in India (Tata Memorial Hospital, AIIMS), Singapore (NCC), and Germany at costs that may be substantially lower than UK private sector prices for self-funded international patients.

Given the rarity of PCNSL and the toxicity of standard intensive treatment, several alternative and emerging approaches are under active investigation:

Reduced-Intensity Protocols for Elderly/Frail Patients

For patients aged 70+ or those with significant comorbidities, reduced-intensity HD-MTX (1.5–3.5 g/m² based on renal function) ± rituximab ± temozolomide represents a less toxic alternative to full MATRix. The MARTA regimen (MTX + arabinoside + rituximab + thiotepa) and IELSG-43 trial are evaluating adapted approaches for older patients. Prognosis remains poor in elderly patients (>70 years) with ECOG PS ≥2 and high IELSG scores.

BTK Inhibitor-Based Combinations

The near-universal prevalence of MYD88 L265P and CD79B mutations in PCNSL provides a compelling biological rationale for BTK inhibitor-based therapy. Multiple phase II trials are evaluating ibrutinib, zanubrutinib, and acalabrutinib in combination with HD-MTX or rituximab-based regimens in both newly diagnosed and relapsed/refractory PCNSL. Preliminary data suggest high response rates and CNS penetration.

CAR-T Cell Therapy

CD19-directed CAR-T cell therapies (tisagenlecleucel, axicabtagene ciloleucel, lisocabtagene maraleucel) have demonstrated efficacy in systemic DLBCL and are being evaluated for PCNSL. The CNS sanctuary — historically a site of CAR-T failure — may paradoxically be advantageous for CNS-targeted infusions. Phase I/II trials (including CAR-T cells delivered intrathecally) are ongoing.

Checkpoint Immunotherapy

PD-L1 expression is detected in approximately 25–30% of PCNSL tumours. Case reports and small series have demonstrated responses to pembrolizumab and nivolumab in relapsed/refractory PCNSL, but prospective trial data remain limited. Autoimmune neurological complications (immune-related encephalitis) are an important concern in this intracranial context.

Palliative Care

For patients with ECOG PS 3–4, significant comorbidities, or who decline intensive chemotherapy, best supportive care with corticosteroids (which often produce dramatic but short-lived responses of weeks to months), symptom management, and early specialist palliative care input should be offered without delay. Dexamethasone, while not curative, can improve neurological symptoms substantially and maintain quality of life for a meaningful period.

Clinical trial participation should be the priority for all eligible patients at both first-line and relapsed/refractory settings, given the rarity of PCNSL and the need for evidence generation to improve outcomes.